OTHER
Therapeutics
Review: rivastigmine reduces rate of cognitive decline and improves performance in mild to moderate Alzheimers
| The first 150 words of the full text of this article appear below. |
Is rivastigmine effective for the treatment of Alzheimers disease?
Cognitive function (measured by psychometric tests); dependency; global impression; functional performance; behavioural disturbance; quality of life; rates of institutionalisation; effect on carer; acceptability of treatment as measured by withdrawal from trials; adverse effects; death.
Systematic review with meta-analysis.
The Specialised Register of the Cochrane Dementia and Cognitive Improvement Group (searched from date of inception to December 2005). The Cochrane Library, MEDLINE, PsycINFO, EMBASE, CINAHL and LILACS were searched for records added after December 2005 to March 2008; ongoing and other unpublished trials searched through Novartis, FDA, EMEA, NICE, Google and Copernic websites.
Randomised, double blind, placebo controlled trials of rivastigmine administered to patients with Alzheimers disease or probable Alzheimers disease (fulfilling DSM-IV or NINCDS-ADRDA) for more than 2 weeks. Exclusions: non-randomised trials; no allocation concealment. A single reviewer selected studies and assessed the quality of included trials on the basis
Aurus IEPE-Institute of Research and Education on Ageing, Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Brazil
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
